Trichosporon Asahii Superinfection in a Patient with COVID-19

Year 2022, Volume: 75 Issue: 3, 472 - 474, 18.10.2022

Serdar Budak , Gülseren Yılmaz , Ebru Kaya , Ramazan Ahmet Altunbay Tuğçe Bayer , Gizem Cinel Emirhan Kahraman , Okan Kölgeli Ayça Sultan Şahin , Ümmühan Topal Ziya Salihoğlu

Abstract

The use of immunosuppressant drugs to treat immunological storms in patients with severe coronavirus disease-2019 (COVID-19) infection has
increased considerations concerning fungal infections. In this patient subset with immune compromise, Trichosporon Asahii (T. asahii) may cause
significant mortality. In this case report, a 60-year-old patient who developed T. Asahii fungemia while being followed in the intensive care unit
due to COVID-19 pneumonia was presented.

Keywords

COVID-19 , Trichosporon Asahii , Superinfection

Ethical Statement

Consent form was filled out by all participants.

Supporting Institution

-

Project Number

-

Thanks

-

COVID-19 Hastasında Trichosporon Asahii Süperenfeksiyonu

Abstract

Şiddetli koronavirüs hastalığı-2019 (COVID-19) enfeksiyonu olan hastalarda immünolojik fırtınaları tedavi etmek için immünosüpresan ilaçların
kullanılması, mantar enfeksiyonlarına ilişkin endişeleri artırmıştır. Trichosporon Asahii (T. asahii), özellikle kritik hastalarda ve bağışıklığı baskılanmış
bireylerde önemli mortaliteye sahip, oldukça dirençli bir patojendir. Bu olgu sunumunda, COVID-19 pnömonisi nedeniyle yoğun bakım ünitesinde
takip edilirken T. Asahii fungemisi gelişen 60 yaşında bir hasta sunulmaktadır.

Keywords

COVID-19 , Trichosporon Asahii , Süperenfeksiyon

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Arastehfar A, Carvalho A, Nguyen MH, et al. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? J Fungi (Basel). 2020;6:211.
• 2. Liao Y, Lu X, Yang S, Luo Y, Chen Q, Yang R, editors. Epidemiology and outcome of Trichosporon fungemia: a review of 185 reported cases from 1975 to 2014. Open forum infectious diseases; 2015: Oxford University Press.
• 3. Li H, Guo M, Wang C, et al. Epidemiological study of Trichosporon asahii infections over the past 23 years. Epidemiol Infect. 2020;148:e169.
• 4. Nobrega de Almeida J Jr, Moreno L, Francisco EC, et al. Trichosporon asahii superinfections in critically ill COVID-19 patients overexposed to antimicrobials and corticosteroids. Mycoses. 2021;64:817-822.
• 5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.
• 6. Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020;185:599-606.
• 7. Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta analysis. JAMA. 2020;324:1330-1341.
• 8. Segrelles-Calvo G, Glauber RDS, Llopis-Pastor E, et al. Trichosporon asahii as cause of nosocomial pneumonia in patient with COVID-19: a triple Coinfection. Arch Bronconeumol. 2021;57:46. 9. Ali GA, Husain A, Salah H, et al. Trichosporon asahii fungemia and COVID-19 co-infection: An emerging fungal pathogen; case report and review of the literature. IDCases. 2021;25:e01244.